First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup, announced the first patient enrolled in a Phase I dose-escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC).
Study Provides Preliminary Evidence in Favor of a New Type 1 Diabetes Treatment
Researchers have discovered preliminary evidence for a new type 1 diabetes treatment using the drug DFMO, supplied by UF startup Panbela Therapeutics.
Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced positive preclinical data supporting the activity of SBP-101 in ovarian cancer cell lines.
Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1b Trial Investigating SBP-101 Combination Therapy for First-Line Metastatic Pancreatic Cancer
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020.
